Tag: Heart Attacks
-
Xeljanz Safety Study Final Data Details the Increased Risks of Cancers and Major Adverse Cardiovascular Events
January 2022 Medical Journal Article Presents Full Set of Findings for the Xeljanz "ORAL Surveillance" Trial Which Started in 2014 (Posted by Tom Lamb at Drug Injury Watch) One year ago Pfizer released some preliminary…
-
Eli Lilly Attempts to Distance Olumiant From the Ominous JAK Inhibitors Drug Class Safety Issues Flagged by FDA
Xeljanz, Rinvoq, and Olumiant Are the Three Janus Kinase (JAK) Inhibitors Getting "Black-Box" Warnings Revisions, Soon (Posted by Tom Lamb at Drug Injury Watch) In September 2021 the FDA announced it was requiring revisions to…
-
Xeljanz Risks of Cardiovascular Events, as Well as Cancers, Cause More Xeljanz Use Limitations
October 2021 UK’s MHRA Xeljanz Action Follows September 2021 FDA Xeljanz Drug Safety Communication Update (Posted by Tom Lamb at Drug Injury Watch) On September 1, 2021, we posted this article, “Xeljanz: FDA Warnings Updated:…
-
Tasigna Lawsuits Federal Court MDL Order Issued in August 2021 After July 2021 JPML Hearing
Consolidation of Tasigna Drug Injury Cases Involving Atherosclerosis-related Diseases and Medical Conditions (Posted by Tom Lamb at Drug Injury Watch) On August 12, 2021, the United States Judicial Panel on Multidistrict Litigation (JPML) created a…
-
Uloric Side Effects Lead To An Increased Risk of Patient Cardiovascular Deaths, Says Health Canada
Drug Safety Warning: Watch For Myocardial Infarction, Stroke, And Cardiac Failure In People Who Are Taking Uloric (Posted by Tom Lamb at DrugInjuryWatch.com) In early November 2019 Health Canada warned that in…
-
Uloric Lawsuits Involving Heart Attacks And Strokes Follow Recent FDA Warnings About Cardiovascular Deaths
February 2019 Uloric Label Changes Include New "Black-Box Warning" To The Effect That Uloric Is Gout Drug Of Last Resort (Posted by Tom Lamb at DrugInjuryWatch.com) As a result of recent FDA-mandated…
-
DPP-4 Diabetes Drug Side Effects Include Heart Attacks And Strokes As Well As Heart Failure
Onglyza, Nesina, Januvia, and Tradjenta Are Included In This Popular Class Of Type-2 Diabetes Medications (Posted by Tom Lamb at DrugInjuryWatch.com) In April 2016 the FDA took regulatory action by mandating label…
-
2018 Emerging Drug Litigations: Viberzi and Actemra
Additional information concerning the potentially harmful side effects of Viberzi and Actemra was released over the course of 2017, and we will continue to monitor the situation in 2018.